Merck & Co, Accenture and UPS are all set to exit application integration and data management platform developer Liaison Technologies through the acquisition.

Oxford University Innovation has released its quarterly figures that reveal more than 89% of external investments in its spinouts occurred in August.

SMS Group has backed a $19.5m series C for Omeicos Therapeutics to enable the Helmholtz spinout to advance its treatment for atrial fibrillation into a phase 2 trial.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux-backed synthetic DNA producer Twist Bioscience floated at the bottom of its range.

The Japan-based insurer will partner TransLink Capital for sub-$5m investments and participate in larger deals itself, branching into areas like blockchain, IoT and healthtech.

UCL Technology Fund-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

Ariel University spinout Innoging has made its public debut and will commercialise ultrasound technology that lets radiologists manipulate scans without the patient being present.

GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.